Skip to main content
FUSION ANTIBODIES PLC logo

FUSION ANTIBODIES PLC — Investor Relations & Filings

Ticker · FAB ISIN · GB00BDQZGK16 LEI · 213800KBAYRC9VOQ9V39 IL Professional, scientific and technical activities
Open in API
Filings indexed 301 across all filing types
Latest filing 2024-03-11 Regulatory Filings
Country GB United Kingdom
Listing IL FAB

About FUSION ANTIBODIES PLC

https://www.fusionantibodies.com/

Fusion Antibodies PLC is a contract research organization (CRO) that provides a comprehensive suite of services for the discovery, engineering, and supply of preclinical biologics. The company offers an integrated, end-to-end antibody development platform, spanning from initial antigen design and antibody generation to advanced engineering processes like humanization and affinity maturation. It also provides services for the supply of recombinant proteins and antibodies, including stable cell line development. Fusion Antibodies supports therapeutic and diagnostic programs, operating as a collaborative partner to guide projects through critical preclinical stages with a focus on long-term manufacturability and commercialization.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Regulatory Filings Classification · 98% confidence The document is explicitly titled 'TR-1: Standard form for notification of major holdings' and contains an 'RNS Number' (3322G). It details changes in voting rights percentages (crossing thresholds) held by Rathbones Investment Management Ltd and related entities, which is characteristic of insider trading or major shareholder disclosure. This type of filing, especially when originating from the RNS system of the London Stock Exchange, falls under regulatory disclosure concerning share ownership changes. While it is a specific regulatory filing, it does not match the specific definitions for DIRS (Director's Dealing) or SHA (Share Issue). The most appropriate general category for mandatory regulatory disclosures that aren't specifically covered by other detailed codes (like 10-K, ER, DEF 14A) is 'Regulatory Filings' (RNS), as it is a standard notification form published via the RNS system.
2024-03-11 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is clearly identified as an 'RNS Number' filing from 'Fusion Antibodies PLC' dated '08 March 2024'. The title of the form is 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, specifically when a shareholder crosses a notification threshold. This directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it is distributed via RNS, the specific content dictates the classification over the general RNS fallback.
2024-03-08 English
Result of General Meeting and Total Voting Rights
AGM Information Classification · 99% confidence The document is identified by the RNS Number header and the presence of 'RNS Number : 6411F' and the closing statement referencing 'RNS, the news service of the London Stock Exchange.' The content explicitly announces the 'Result of General Meeting' and provides the 'Total Voting Rights' following the meeting and associated share placement. This directly corresponds to the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it is an RNS filing, DVA is the more specific category for the content provided.
2024-03-05 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content announces the 'Total Voting Rights' (60,990,564 ordinary shares) as of a specific date (29 February 2024). This type of mandatory disclosure regarding share capital and voting rights, distributed via the Regulatory News Service (RNS), fits best under the general 'Regulatory Filings' category, as there is no specific code for 'Total Voting Rights' announcements, and it is not a full financial report (10-K, IR) or a management change (MANG). It is a standard regulatory update.
2024-02-29 English
First purchase order under MSA
Regulatory Filings Classification · 100% confidence The document begins with an 'RNS Number' and is dated February 27, 2024. It announces a specific business event: receiving a first purchase order under a previously announced Master Services Agreement (MSA) with a diagnostics company. This type of announcement, detailing a specific operational or commercial update that is not a full financial report (like 10-K or IR), dividend, or management change, is characteristic of a general regulatory news service release. Since it is a specific, non-standard announcement distributed via RNS (London Stock Exchange's news service), and it doesn't fit the definitions for ER, DIV, MANG, or CAP, the most appropriate classification is the general regulatory announcement category, RNS.
2024-02-27 English
Grant of options and issue of shares to directors
Remuneration Information Classification · 100% confidence The document is identified by the header 'RNS Number : 0382D' and contains standard regulatory disclosure language, including references to the London Stock Exchange and the Financial Conduct Authority (FCA). The content details the grant of share options and the issue of shares to directors in lieu of salary. This type of announcement, which reports on insider transactions (Director's Dealing) and compensation/share structure changes, is typically disseminated via regulatory news services. While it contains elements of Director's Dealing (DIRS) and Share Issue (SHA), the overall structure and the explicit mention of 'RNS' and the nature of the disclosure (notification of transactions by persons discharging managerial responsibilities) strongly suggest it is a general regulatory announcement disseminated through the RNS system. Since 'Director's Dealing' (DIRS) is a specific category for insider trades, and this document explicitly details transactions by directors (grant of options and issue of shares for salary), DIRS is the most precise fit for the core subject matter, even though it is distributed via RNS. However, looking closely at the definitions, the document is a formal notification of transactions by PDMRs (Persons Discharging Managerial Responsibilities) regarding share issues and option grants. This falls under the scope of insider reporting, which is best captured by DIRS (Director's Dealing). The final section explicitly details 'Notification and public disclosure of transactions by persons discharging managerial responsibilities'.
2024-02-14 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.